NCT05730088 Reducing the Number of Hospital Admissions With Multiple Nursing Interventions in COPD Patients Using Oxygen Concentrators at Home
| NCT ID | NCT05730088 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Necmettin Erbakan University |
| Condition | Pulmonary Disease, Chronic Obstructive |
| Study Type | INTERVENTIONAL |
| Enrollment | 74 participants |
| Start Date | 2023-02-15 |
| Primary Completion | 2023-08-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 74 participants in total. It began in 2023-02-15 with a primary completion date of 2023-08-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by persistent airflow obstruction and chronic respiratory symptoms or alpha-1-antitrypsin deficiency in response to inhaled cigarette smoke or other irritants. The excessive morbidity and mortality associated with COPD acute exacerbations represent a significant public health problem that places a high burden on patients, their families and society. In frequent and severe exacerbations, patients may experience a decrease in quality of life, depression, and even death up to one year after hospitalization. Costs associated with COPD are more than $15.5 billion, and hospitalizations and repeated hospital admissions related to acute exacerbations alone account for 70% of all costs. For these reasons, efforts to reduce hospital admissions and hospitalizations associated with recurrent exacerbations are imperative to improve patient's quality of life and reduce the societal burden.
Eligibility Criteria
Inclusion Criteria: * Being diagnosed with stage 4 (group D) COPD according to GOLD criteria * Being 18 years or older, * Having a video computer, tablet or phone, * Having an internet connection at home or on the phone, * Residing in the city centre of Konya, * Not having a communication problem, such as an inability to understand/speak Turkish, that would prevent participation in the research, * Being literate, * Using an oxygen concentrator at home. Exclusion Criteria: * Being illiterate, * Being diagnosed with first, second and third-stage COPD according to GOLD criteria, * Having another lung disease in addition to COPD (Lung cancer-Asthma, etc.), * Having physical and/or mental disabilities, * Being visually impaired and/or hearing impaired, * Having a communication problem that prevents participation in the research, such as an inability to understand/speak Turkish, * Having been diagnosed with Covid-19 or having had it in the past, * Having a psychiatric disease
Contact & Investigator
DİLEK CİNGİL
PRINCIPAL INVESTIGATOR
https://erbakan.edu.tr/hemsirelikfak
Frequently Asked Questions
Who can join the NCT05730088 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pulmonary Disease, Chronic Obstructive. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05730088 currently recruiting?
Yes, NCT05730088 is actively recruiting participants. Contact the research team at smhasanbakir@gmail.com for enrollment information.
Where is the NCT05730088 trial being conducted?
This trial is being conducted at Konya, Turkey (Türkiye).
Who is sponsoring the NCT05730088 clinical trial?
NCT05730088 is sponsored by Necmettin Erbakan University. The principal investigator is DİLEK CİNGİL at https://erbakan.edu.tr/hemsirelikfak. The trial plans to enroll 74 participants.